Voyager Therapeutics, Inc. (VYGR) Net margin 2016–2025
Voyager Therapeutics, Inc. (VYGR) net profit margin by fiscal year — reported net income divided by reported revenue.
-296.5%FY2025 · since FY2016: -282.7% → -296.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -296.5% | -215.3 pp |
| FY2024 | -81.3% | -134.2 pp |
| FY2023 | 52.9% | +166.4 pp |
| FY2022 | -113.4% | +76.8 pp |
| FY2021 | -190.3% | -211.8 pp |
| FY2020 | 21.5% | +63.2 pp |
| FY2019 | -41.8% | +1117.0 pp |
| FY2018 | -1158.8% | -461.2 pp |
| FY2017 | -697.6% | -414.9 pp |
| FY2016 | -282.7% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More VYGR financial trends
VYGR RevenueVYGR Net incomeVYGR Gross profitVYGR Gross marginVYGR Operating incomeVYGR Operating marginVYGR Operating cash flowVYGR Free cash flowVYGR Capital expendituresVYGR Return on equityVYGR Stock buybacksVYGR Dividends paidVYGR Total assetsVYGR Total liabilitiesVYGR Shareholders’ equityVYGR overview →